Search results
Merck's CEO to succeed Ken Frazier as chairman
Reuters via Yahoo Finance· 2 years agoFrazier, who has been a key growth driver of the drugmaker for decades, joined Merck around 30 years ago and became the first Black CEO of a major drug...
Drugmakers' shares stabilise after Zantac litigation slump
Reuters via Yahoo Finance· 2 years agoShares in GSK, Sanofi, Haleon and Pfizer began to recover on Friday after the companies said that...
Haleon believes it is not liable for any potential Zantac liabilities
Reuters via Yahoo Finance· 2 years agoLONDON (Reuters) -Haleon believes it is not liable for any claims that may arise from U.S....
Top FDA official Woodcock to retire early next year
BioPharma Dive via Yahoo Finance· 7 months agoThe 37-year veteran helmed the agency’s pandemic response, and was a key decision-maker in controversial calls on opioids, an Alzheimer's therapy and...
GSK, Sanofi shares soar as Zantac litigation fears abate
Reuters via Yahoo Finance· 1 year agoShares of GSK and Sanofi surged on Wednesday, adding more than $20 billion in combined value in...
New GSK maintains strong start, but Zantac litigation looms large
Reuters via Yahoo Finance· 2 years ago(Reuters) -GSK raised its 2022 forecast for the second time this year, after third-quarter earnings...
GSK, Sanofi and Haleon shares slump on Zantac litigation concerns
Reuters via Yahoo Finance· 2 years agoLONDON (Reuters) -Shares in GSK, Sanofi and Haleon fell sharply on Thursday, following declines...
UPDATE 2-GSK lifts earnings view again after forecast-beating quarter
Reuters via Yahoo Finance· 2 years ago* Q3 adjusted EPS 46.9 pence vs forecast 40.1 pence * Sees 2022 adj op profit up 15-17% vs up 13-15% before (Adds details, background) By Natalie Grover Nov 2 (Reuters) - GSK eclipsed analyst ...
UPDATE 2-Haleon rejects Zantac indemnification requests from GSK, Pfizer
Reuters via Yahoo Finance· 2 years agoHaleon on Tuesday said it had notified GSK and Pfizer that it had rejected their requests for indemnification in relation to U.S.-based litigation over the heartburn drug, Zantac. More than ...
Are drugs promoted on TV ads better than others? No, study finds. Sometimes they're worse.
USA TODAY via Yahoo News· 1 year agoThey often start with someone in late-middle-age, gray-haired but active, taking a brisk hike, biking or looking out to sea. There's a passing reference to some dreaded disease the person would ...
